Fox Chase Researcher Finds Genetic Differences in Rare Kidney Cancer Subtype That Could Lead to More Effective Treatment
PHILADELPHIA (February 22, 2024) — TFE3-rearranged renal cell carcinoma (rRCC) is a rare subtype of kidney cancer that can be misdiagnosed. This can affect treatment decisions and lead to patients receiving the wrong type of treatment. Now, a recently published study by scientists at Fox Chase Cancer Center identifies key genetic markers that can be used to distinguish rRCC from other cancers and also confirms which therapies are likely to be most effective.
VIEW STORY